Reversal and Preventive Pleiotropic Mechanisms Involved in the Antipsychotic-Like Effect of Taurine, an Essential β-Amino Acid in Ketamine-Induced Experimental Schizophrenia in Mice
- PMID: 36350433
- DOI: 10.1007/s11064-022-03808-5
Reversal and Preventive Pleiotropic Mechanisms Involved in the Antipsychotic-Like Effect of Taurine, an Essential β-Amino Acid in Ketamine-Induced Experimental Schizophrenia in Mice
Abstract
Schizophrenia is a life disabling, multisystem neuropsychiatric disease mostly derived from complex epigenetic-mediated neurobiological changes causing behavioural deficits. Neurochemical disorganizations, neurotrophic and neuroimmune alterations are some of the challenging neuropathologies proving unabated during psychopharmacology of schizophrenia, further bedeviled by drug-induced metabolic derangements including alteration of amino acids. In first-episode schizophrenia patients, taurine, an essential β-amino acid represses psychotic-symptoms. However, its anti-psychotic-like mechanisms remain incomplete. This study evaluated the ability of taurine to prevent or reverse ketamine-induced experimental psychosis and the underlying neurochemical, neurotrophic and neuroinmune mechanisms involved in taurine's clinical action. The study consisted of three different experiments with Swiss mice (n = 7). In the drug alone, mice received saline (10 mL/kg/p.o./day), taurine (50 and 100 mg/kg/p.o./day) and risperidone (0.5 mg/kg/p.o./day) for 14 days. In the preventive study of separate cohort, mice were concomitantly given ketamine (20 mg/kg/i.p./day) from days 8 to 14. In the reversal study, mice received ketamine for 14 days before taurine or risperidone treatments from days 8 to 14 respectively. Afterwards, stereotypy behaviour, social, non-spatial memory deficits, and body weights were assessed. Neurochemical (dopamine, 5-hydroxytryptamine, glutamic acid decarboxylase, (GAD)), brain derived-neurotrophic factor (BDNF) and pro-inflammatory cytokines [tumor necrosis factor-alpha, (TNF-α), interleukin-6, (IL-6)] were assayed in the striatum, prefrontal-cortex and hippocampal area. Taurine attenuates ketamine-induced schizophrenia-like behaviour without changes in body weight. Taurine reduced ketamine-induced dopamine and 5-hydroxytryptamine changes, and increased GAD and BDNF levels in the striatum, prefrontal-cortex and hippocampus, suggesting increased GABAergic and neurotrophic transmissions. Taurine decreases ketamine-induced increased in TNF-α and IL-6 concentrations in the striatum, prefrontal-cortex and hippocampus. These findings also suggest that taurine protects against schizophrenia through neurochemical modulations, neurotrophic enhancement, and inhibition of neuropathologic cytokine activities.
Keywords: Amino acids; Antipsychotics; BDNF; Neurotransmitters; Schizophrenia; Taurine.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.Brain Res Bull. 2018 May;139:292-306. doi: 10.1016/j.brainresbull.2018.03.006. Epub 2018 Mar 13. Brain Res Bull. 2018. PMID: 29548911
-
Taurine, an essential β-amino acid insulates against ketamine-induced experimental psychosis by enhancement of cholinergic neurotransmission, inhibition of oxidative/nitrergic imbalances, and suppression of COX-2/iNOS immunoreactions in mice.Metab Brain Dis. 2022 Dec;37(8):2807-2826. doi: 10.1007/s11011-022-01075-5. Epub 2022 Sep 3. Metab Brain Dis. 2022. PMID: 36057735
-
Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action.J Psychiatr Res. 2024 Nov;179:141-155. doi: 10.1016/j.jpsychires.2024.09.003. Epub 2024 Sep 12. J Psychiatr Res. 2024. PMID: 39293119
-
Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.Eur Neuropsychopharmacol. 2008 Nov;18(11):773-86. doi: 10.1016/j.euroneuro.2008.06.005. Epub 2008 Jul 23. Eur Neuropsychopharmacol. 2008. PMID: 18650071 Free PMC article. Review.
-
Serotonin and dopamine interactions in psychosis prevention.Prog Brain Res. 2008;172:141-53. doi: 10.1016/S0079-6123(08)00907-2. Prog Brain Res. 2008. PMID: 18772031 Review.
Cited by
-
Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice.J Neural Transm (Vienna). 2024 Aug;131(8):971-986. doi: 10.1007/s00702-024-02793-z. Epub 2024 Jun 14. J Neural Transm (Vienna). 2024. PMID: 38874765
-
Brain-derived neurotrophic factor (BDNF) changes in rodent models of schizophrenia induced by ketamine: a systematic review.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul;398(7):8111-8124. doi: 10.1007/s00210-025-03912-7. Epub 2025 Feb 20. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39976721
-
Emerging epigenetic dynamics in gut-microglia brain axis: experimental and clinical implications for accelerated brain aging in schizophrenia.Front Cell Neurosci. 2023 May 15;17:1139357. doi: 10.3389/fncel.2023.1139357. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37256150 Free PMC article. Review.
-
Inhibition of oxidative stress, neuroinflammatory cytokines, and protein expressions contributes to the antipsychotic effects of geraniol in mice with ketamine-induced schizophrenia.J Neuroimmune Pharmacol. 2025 Jul 3;20(1):70. doi: 10.1007/s11481-025-10226-1. J Neuroimmune Pharmacol. 2025. PMID: 40608148
-
The protective role of ginsenoside Rg3 in heart diseases and mental disorders.Front Pharmacol. 2024 Feb 26;15:1327033. doi: 10.3389/fphar.2024.1327033. eCollection 2024. Front Pharmacol. 2024. PMID: 38469409 Free PMC article. Review.
References
-
- Dietrich-Muszalska A, Kolodziejczyk-Czepas J, Nowak P (2021) Comparative study of the effects of atypical antipsychotic drugs on plasma and urine biomarkers of oxidative stress in schizophrenic patients. Neuropsychiatr Dis Treat 17:555–565. https://doi.org/10.2147/NDT.S283395 - DOI
-
- Chatterjee M, Verma R, Ganguly S, Palit G (2012) Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology 63(6):1161–1171. https://doi.org/10.1016/j.neuropharm.2012.05.041 - DOI
-
- Howes O, McCutcheon R, Stone J (2015) Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 29(2):97–115. https://doi.org/10.1177/0269881114563634 - DOI
-
- Zhang XY et al (2016) Interaction of BDNF with cytokines in chronic schizophrenia. Brain Behav Immun 51:169–175. https://doi.org/10.1016/j.bbi.2015.09.014 - DOI
-
- Comer AL, Carrier M, Tremblay M-È, Cruz-Martín A (2020) The inflamed brain in schizophrenia: the convergence of genetic and environmental risk factors that lead to uncontrolled neuroinflammation. Front Cell Neurosci 14:274. https://doi.org/10.3389/fncel.2020.00274 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical